+1 609 818 9500

Support 24/7

0Your Cart$0.00

Cart (0)

No products in the cart.

Granicip 1 Mg


Generic:              Granisetron
Manufacturer:   Cipla Ltd
Pack size:          28 Tablet/s, 56 Tablet/s, 84 Tablet/s    
Pharma Form:   Tablet
Strength:            1 mg
Uses:                  Gastro Health

3000 products available

Pack Size:

Categories: Gastro Health
Free Shipping
Free Shipping
For all orders over $199
1 & 1 Returns
1 & 1 Returns
Cancellation after 1 day
Secure Payment
Secure Payment
Guarantee secure payments

Granicip, 1 mg 


Pharmaceutical marvel Granicip 1 mg is indispensable for the management of nausea and vomiting brought on by a variety of medical procedures, especially radiation therapy and chemotherapy. The active constituent in this medication is granisetron, which is classified as a 5-HT3 receptor antagonist. Analyze Granicip 1 mg in detail, exploring its functions, mechanism of action, advantages, and relevant factors. 


Understanding Granicip 1 mg: 


Doctors primarily prescribe Granicip 1 mg to alleviate the distressing side effects of nausea and vomiting associated with cancer treatments, which are often faced by patients undergoing chemotherapy or radiation. Granisetron, the active ingredient, works by blocking the action of serotonin, a neurotransmitter involved in triggering nausea and vomiting signals in the brain. 


Applications in Cancer Treatment: 


The primary application of Granicip 1 mg is in the field of oncology, where cancer patients undergoing chemotherapy or radiation therapy may experience severe nausea and vomiting. These side effects, if left unmanaged, can significantly impact the quality of life for patients and may even lead to treatment discontinuation. Granicip steps in to mitigate these symptoms, providing relief and allowing individuals to better tolerate their cancer treatments. 


The mechanism of action: 


Granicip's efficacy lies in its ability to antagonise serotonin receptors, particularly the 5-HT3 receptors, in the central nervous system and the gastrointestinal tract. By inhibiting the action of serotonin, Granicip disrupts the signals that trigger nausea and vomiting, offering patients a reprieve from these distressing symptoms. 


Benefits and Efficacy: 


One of the standout benefits of Granicip 1 mg is its effectiveness in preventing and managing chemotherapy-induced and radiation-induced nausea and vomiting. By providing prophylactic relief, Granicip contributes to an improved treatment experience for cancer patients, fostering better adherence to their therapeutic regimens. 


Considerations and Usage: 


Granicip 1 mg is typically administered orally, and in certain cases, it may be prescribed in the form of an injection. It is important for healthcare providers to tailor the dosage and administration method based on the specific needs and condition of each patient. As with any medication, individuals using Granicip should communicate their medical history, including any allergies or concurrent medications, to ensure a safe and effective treatment plan. 


Future Perspectives: 


As research in oncology and supportive care continues, the role of medications like Granicip in alleviating treatment-related side effects is likely to evolve. Ongoing advancements may lead to refined formulations or innovative approaches, further enhancing the efficacy and tolerability of antiemetic medications in cancer care. 

Add your review

Your email address will not be published. Required fields are marked *

Please login to write review!

Upload photos

Looks like there are no reviews yet.

Related products